|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), : Long-term outcomes for neoadjuvant
versus adjuvant chemotherapy in early breast cancer: Meta-analysis
of individual patient data from ten randomised trials. Lancet
Oncol. 19:27–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esserman LJ, Berry DA, Cheang MC, Yau C,
Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg
ME, et al: Chemotherapy response and recurrence-free survival in
neoadjuvant breast cancer depends on biomarker profiles: Results
from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast
Cancer Res Treat. 132:1049–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foekens JA, Romain S, Look MP, Martin PM
and Klijn JG: Thymidine kinase and thymidylate synthase in advanced
breast cancer: Response to tamoxifen and chemotherapy. Cancer Res.
61:1421–1425. 2001.PubMed/NCBI
|
|
7
|
Yu Z, Yang Q, Sun J and Zhen J:
Dihydropyrimidine dehydrogenase activity correlates with
fluorouracil sensitivity in breast cancer. Exp Oncol. 29:192–196.
2007.PubMed/NCBI
|
|
8
|
Trock BJ, Leonessa F and Clarke R:
Multidrug resistance in breast cancer: A meta-analysis of
MDR1/gp170 expression and its possible functional significance. J
Natl Cancer Inst. 89:917–931. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taheri M and Mahjoubi F: MRP1 but not MDR1
is associated with response to neoadjuvant chemotherapy in breast
cancer patients. Dis Markers. 34:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z,
Shao Z and Lu J: The role of topoisomerase IIα in predicting
sensitivity to anthracyclines in breast cancer patients: A
meta-analysis of published literatures. Breast Cancer Res Treat.
129:839–848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tokiniwa H, Horiguchi J, Takata D, Kikuchi
M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T and
Takeyoshi I: Topoisomerase II alpha expression and the Ki-67
labeling index correlate with prognostic factors in estrogen
receptor-positive and human epidermal growth factor type-2-negative
breast cancer. Breast Cancer. 19:309–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu A, Yuan P, Du F, Hong R, Ding X, Shi
X, Fan Y, Wang J, Luo Y, Ma F, et al: SPARC overexpression in
primary tumors correlates with disease recurrence and overall
survival in patients with triple negative breast cancer.
Oncotarget. 7:76628–76634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Framson PE and Sage EH: SPARC and tumor
growth: Where the seed meets the soil? J Cell Biochem. 92:679–690.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brekken RA and Sage EH: SPARC, a
matricellular protein: At the crossroads of cell-matrix
communication. Matrix Biol. 19:816–287. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arnold SA and Brekken RA: SPARC: A
matricellular regulator of tumorigenesis. J Cell Commun Signal.
3:255–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Podhajcer OL, Benedetti LG, Girotti MR,
Prada F, Salvatierra E and Llera AS: The role of the matricellular
protein SPARC in the dynamic interaction between the tumor and the
host. Cancer Metastasis Rev. 27:691–705. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan Q and Sage EH: SPARC, a matricellular
glycoprotein with important biological functions. J Histochem
Cytochem. 47:1495–1506. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bradshaw AD and Sage EH: SPARC, a
matricellular protein that functions in cellular differentiation
and tissue response to injury. J Clin Invest. 107:1049–1054. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Helleman J, Jansen MP, Ruigrok-Ritstier K,
van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn
JG, Sleijfer S, Foekens JA and Berns EM: Association of an
extracellular matrix gene cluster with breast cancer prognosis and
endocrine therapy response. Clin Cancer Res. 14:5555–5564. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang
KJ and Hsieh FJ: SPARC (osteonectin) in breast tumors of different
histologic types and its role in the outcome of invasive ductal
carcinoma. Breast J. 16:305–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azim HA Jr, Singhal S, Ignatiadis M,
Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S
and Sotiriou C: Association between SPARC mrna expression,
prognosis and response to neoadjuvant chemotherapy in early breast
cancer: A pooled in-silico analysis. PLoS One. 8:e624512013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gradishar WJ, Krasnojon D, Cheporov S,
Makhson AN, Manikhas GM, Clawson A and Bhar P: Significantly longer
progression-free survival with nab-paclitaxel compared with
docetaxel as first-line therapy for metastatic breast cancer. J
Clin Oncol. 27:3611–3619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Untch M, Jackisch C, Schneeweiss A, Conrad
B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S,
Hilfrich J, et al: Nab-paclitaxel versus solvent-based paclitaxel
in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG
69): A randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Obayashi S, Horiguchi J, Higuchi T,
Katayama A, Handa T, Altan B, Bai T, Bao P, Bao H, Yokobori T, et
al: Stathmin1 expression is associated with aggressive phenotypes
and cancer stem cell marker expression in breast cancer patients.
Int J Oncol. 51:781–790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
26
|
Ledda F, Bravo AI, Adris S, Bover L,
Mordoh J and Podhajcer OL: The expression of the secreted protein
acidic and rich in cysteine (SPARC) is associated with the
neoplastic progression of human melanoma. J Invest Dermatol.
108:210–214. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rempel SA, Golembieski WA, Fisher JL,
Maile M and Nakeff A: SPARC modulates cell growth, attachment and
migration of U87 glioma cells on brain extracellular matrix
proteins. J Neurooncol. 53:149–160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thomas R, True LD, Bassuk JA, Lange PH and
Vessella RL: Differential expression of osteonectin/SPARC during
human prostate cancer progression. Clin Cancer Res. 6:1140–1149.
2000.PubMed/NCBI
|
|
29
|
Liu QZ, Gao XH, Chang WJ, Wang HT, Wang H,
Cao GW and Fu CG: Secreted protein acidic and rich in cysteine
expression in human colorectal cancer predicts postoperative
prognosis. Eur Rev Med Pharmacol Sci. 19:1803–1811. 2015.PubMed/NCBI
|
|
30
|
Guweidhi A, Kleeff J, Adwan H, Giese NA,
Wente MN, Giese T, Büchler MW, Berger MR and Friess H: Osteonectin
influences growth and invasion of pancreatic cancer cells. Ann
Surg. 242:224–134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang CS, Lin KH, Chen SL, Chan YF and
Hsueh S: Overexpression of SPARC gene in human gastric carcinoma
and its clinic-pathologic significance. Br J Cancer. 91:1924–1930.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yiu GK, Chan WY, Ng SW, Chan PS, Cheung
KK, Berkowitz RS and Mok SC: SPARC (secreted protein acidic and
rich in cysteine) induces apoptosis in ovarian cancer cells. Am J
Pathol. 159:609–622. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iacobuzio-Donahue CA, Argani P, Hempen PM,
Jones J and Kern SE: The desmoplastic response to infiltrating
breast carcinoma: Gene expression at the site of primary invasion
and implications for comparisons between tumor types. Cancer Res.
62:5351–5357. 2002.PubMed/NCBI
|
|
34
|
Nagai MA, Gerhard R, Fregnani JH, Nonogaki
S, Rierger RB, Netto MM and Soares FA: Prognostic value of NDRG1
and SPARC protein expression in breast cancer patients. Breast
Cancer Res Treat. 126:1–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schneeweiss A, Seitz J, Smetanay K,
Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP and Marmé F:
Efficacy of nab-paclitaxel does not seem to be associated with
SPARC expression in metastatic breast cancer. Anticancer Res.
34:6609–6615. 2014.PubMed/NCBI
|
|
36
|
Lindner JL, Loibl S, Denkert C, Ataseven
B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S,
Sinn BV, et al: Expression of secreted protein acidic and rich in
cysteine (SPARC) in breast cancer and response to neoadjuvant
chemotherapy. Ann Oncol. 26:95–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yardley DA: Nab-Paclitaxel mechanisms of
action and delivery. J Control Release. 170:365–372. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Desai NP, Trieu V, Hwang LY, Wu R,
Soon-Shiong P and Gradishar WJ: Improved effectiveness of
nanoparticle albumin-bound (nab) paclitaxel versus
polysorbate-based docetaxel in multiple xenografts as a function of
HER2 and SPARC status. Anticancer Drugs. 19:899–909. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Graham JD, Balleine RL, Milliken JS,
Bilous AM and Clarke CL: Expression of osteonectin mrna in human
breast tumours is inversely correlated with oestrogen receptor
content. Eur J Cancer. 33:1654–1660. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kurozumi S, Matsumoto H, Hayashi Y, Tozuka
K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T and Kurosumi M: Power
of PgR expression as a prognostic factor for
ER-positive/HER2-negative breast cancer patients at intermediate
risk classified by the Ki67 labeling index. BMC Cancer. 17:3542017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kurozumi S, Matsumoto H, Inoue K, Tozuka
K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J and Kuwano
H: Impact of combining the progesterone receptor and preoperative
endocrine prognostic index (PEPI) as a prognostic factor after
neoadjuvant endocrine therapy using aromatase inhibitors in
postmenopausal ER positive and HER2 negative breast cancer. PLoS
One. 13:e02018462018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kurozumi S, Inoue K, Takei H, Matsumoto H,
Kurosumi M, Horiguchi J, Takeyoshi I and Oyama T: ER, PgR, Ki67,
p27(Kip1), and histological grade as predictors of pathological
complete response in patients with HER2-positive breast cancer
receiving neoadjuvant chemotherapy using taxanes followed by
fluorouracil, epirubicin, and cyclophosphamide concomitant with
trastuzumab. BMC Cancer. 15:6222015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bekki Y, Yoshizumi T, Shimoda S, Itoh S,
Harimoto N, Ikegami T, Kuno A, Narimatsu H, Shirabe K and Maehara
Y: Hepatic stellate cells secreting WFA+-M2BP: Its role
in biological interactions with kupffer cells. J Gastroenterol
Hepatol. 32:1387–1393. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wiese AH, Auer J, Lassmann S, Nährig J,
Rosenberg R, Höfler H, Rüger R and Werner M: Identification of gene
signatures for invasive colorectal tumor cells. Cancer Detect Prev.
31:282–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fisher B, Bryant J, Wolmark N, Mamounas E,
Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux
A, et al: Effect of preoperative chemotherapy on the outcome of
women with operable breast cancer. J Clin Oncol. 16:2672–2685.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bear HD, Anderson S, Smith RE, Geyer CE
Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R,
Kahlenberg MS, et al: Sequential preoperative or postoperative
docetaxel added to preoperative doxorubicin plus cyclophosphamide
for operable breast cancer: National surgical adjuvant breast and
bowel project protocol B-27. J Clin Oncol. 24:2019–2027. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
von Minckwitz G: Neoadjuvant chemotherapy
in breast cancer-insights from the German experience. Breast
Cancer. 19:282–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Puolakkainen PA, Brekken RA, Muneer S and
Sage EH: Enhanced growth of pancreatic tumors in sparc-null mice is
associated with decreased deposition of extracellular matrix and
reduced tumor cell apoptosis. Mol Cancer Res. 2:215–224.
2004.PubMed/NCBI
|
|
51
|
Said N and Motamed K: Absence of
host-secreted protein acidic and rich in cysteine (SPARC) augments
peritoneal ovarian carcinomatosis. Am J Pathol. 167:1739–1752.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim H, Samuel S, Lopez-Casas P, Grizzle W,
Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J and Buchsbaum
D: SPARC-Independent delivery of nab-paclitaxel without depleting
tumor stroma in patient-derived pancreatic cancer xenografts. Mol
Cancer Ther. 15:680–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
